Adaptive Antiviral Immunity Is a Determinant of the Therapeutic Success of Oncolytic Virotherapy

Oncolytic virotherapy, the selective killing of tumor cells by oncolytic viruses (OVs), has emerged as a promising avenue of anticancer research. We have previously shown that KM100, a Herpes simplex virus type-1 (HSV) deficient for infected cell protein 0 (ICP0), possesses substantial oncolytic pro...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Sobol, Paul T, Boudreau, Jeanette E, Stephenson, Kyle, Wan, Yonghong, Lichty, Brian D, Mossman, Karen L
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Nature Publishing Group 2011
Gaiak:
Original Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3034857/
https://ncbi.nlm.nih.gov/pubmed/21119618
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/mt.2010.264
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak